roche-buys-singapore-facility-from-lonza

Roche buys Singapore facility from Lonza

Global healthcare firm Roche, through its subsidiary Genentech, will acquire a Singapore manufacturing facility from Lonza for up to $360 million.

Global healthcare firm Roche will buy a Singapore biologic manufacturing facility for up to $360 million from chemical and biotechnology firm Lonza , the two firms said yesterday.

Basel-based Roche will buy the facility through its San Francisco-headquartered subsidiary Genentech, which it acquired earlier this year. The acquisition price of $360 million has two components a $290 million upfront payment and a $70 million milestone-based payment.

After the takeover, the Lonza facility will be merged with Genentech Singapore's existing facility. The Lonza facility is designed to produce the bulk drug substance for Avastin, a breakthrough chemotherapy drug used to treat colon, rectal and lung cancer, which the US Food and Drug Administration approved for commercial...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222